中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
18期
2751-2753
,共3页
变应性鼻炎%Th1/Th2细胞因子%孟鲁司特
變應性鼻炎%Th1/Th2細胞因子%孟魯司特
변응성비염%Th1/Th2세포인자%맹로사특
Allergic Rhinitis%Th1/Th2 Cytokine%Montelukast
目的 探讨变应性鼻炎患者血清Th1/Th2细胞因子水平的变化及孟鲁司特的干预作用.方法 选择变应性鼻炎患者40例(治疗组)予以孟鲁司特片10 mg口服,1次/d,连用8周.观察患者治疗前后外周血中γ-干扰素(IFN-γ)和白介素-4(IL-4)水平的变化,并进行临床疗效及安全性的观察.另选择同期体检的正常健康者30例作为对照组.结果 治疗组患者治疗前培养上清中IFN-γ水平[(8.74±1.37) ng/mL]明显低于对照组[(15.13 ±3.16) ng/mL],IL-4水平[(1.64±0.47)ng/mL]明显高于对照组[(0.72±0.21) ng/mL](t=2.93、3.52,均P＜0.01).治疗8周后,患者培养上清中IFN-γ水平[(12.36±2.56) ng/mL]均较治疗前[(8.74±1.37) ng/mL]明显上升,IL-4水平[(1.21±0.28) ng/mL]均较治疗前[(1.64±0.47) ng/mL]明显下降(t=2.36、2.31,均P＜0.05);且治疗组治疗8周后,临床总有效率92.5％ (37/40),治疗期间未发生严重的药物不良反应.结论 变应性鼻炎患者存在外周血Th1/Th2细胞因子的失衡.孟鲁司特治疗变应性鼻炎的疗效确切,安全性较好,作用机制与其能降低外周血IL-4水平,提高外周血IFN-γ水平,纠正Th1/Th2细胞因子的平衡紊乱,使免疫反应由Th2型向Th1型转变密切相关.
目的 探討變應性鼻炎患者血清Th1/Th2細胞因子水平的變化及孟魯司特的榦預作用.方法 選擇變應性鼻炎患者40例(治療組)予以孟魯司特片10 mg口服,1次/d,連用8週.觀察患者治療前後外週血中γ-榦擾素(IFN-γ)和白介素-4(IL-4)水平的變化,併進行臨床療效及安全性的觀察.另選擇同期體檢的正常健康者30例作為對照組.結果 治療組患者治療前培養上清中IFN-γ水平[(8.74±1.37) ng/mL]明顯低于對照組[(15.13 ±3.16) ng/mL],IL-4水平[(1.64±0.47)ng/mL]明顯高于對照組[(0.72±0.21) ng/mL](t=2.93、3.52,均P＜0.01).治療8週後,患者培養上清中IFN-γ水平[(12.36±2.56) ng/mL]均較治療前[(8.74±1.37) ng/mL]明顯上升,IL-4水平[(1.21±0.28) ng/mL]均較治療前[(1.64±0.47) ng/mL]明顯下降(t=2.36、2.31,均P＜0.05);且治療組治療8週後,臨床總有效率92.5％ (37/40),治療期間未髮生嚴重的藥物不良反應.結論 變應性鼻炎患者存在外週血Th1/Th2細胞因子的失衡.孟魯司特治療變應性鼻炎的療效確切,安全性較好,作用機製與其能降低外週血IL-4水平,提高外週血IFN-γ水平,糾正Th1/Th2細胞因子的平衡紊亂,使免疫反應由Th2型嚮Th1型轉變密切相關.
목적 탐토변응성비염환자혈청Th1/Th2세포인자수평적변화급맹로사특적간예작용.방법 선택변응성비염환자40례(치료조)여이맹로사특편10 mg구복,1차/d,련용8주.관찰환자치료전후외주혈중γ-간우소(IFN-γ)화백개소-4(IL-4)수평적변화,병진행림상료효급안전성적관찰.령선택동기체검적정상건강자30례작위대조조.결과 치료조환자치료전배양상청중IFN-γ수평[(8.74±1.37) ng/mL]명현저우대조조[(15.13 ±3.16) ng/mL],IL-4수평[(1.64±0.47)ng/mL]명현고우대조조[(0.72±0.21) ng/mL](t=2.93、3.52,균P＜0.01).치료8주후,환자배양상청중IFN-γ수평[(12.36±2.56) ng/mL]균교치료전[(8.74±1.37) ng/mL]명현상승,IL-4수평[(1.21±0.28) ng/mL]균교치료전[(1.64±0.47) ng/mL]명현하강(t=2.36、2.31,균P＜0.05);차치료조치료8주후,림상총유효솔92.5％ (37/40),치료기간미발생엄중적약물불량반응.결론 변응성비염환자존재외주혈Th1/Th2세포인자적실형.맹로사특치료변응성비염적료효학절,안전성교호,작용궤제여기능강저외주혈IL-4수평,제고외주혈IFN-γ수평,규정Th1/Th2세포인자적평형문란,사면역반응유Th2형향Th1형전변밀절상관.
Objective To discuss the changes of serum Th1/Th2 cytokine levels of allergic rhinitis patients and the intervention effect of montelukast.Methods 40 cases of allergic rhinitis patients were selected as treatment group,who were given montelukast tablets (10mg) through the mouth one time daily for 8 weeks.The changes of interferon-γ (IFN-γ) and interleukin-4 (IL-4) in peripheral blood (PB) before and after medical treatment were observed,as well as the clinical curative effect and security.Accordingly 30 cases of healthy people were also selected as the control group.Results The IFN-γlevel in culture supernatant of patients in the treatment group [(8.74 ± 1.37) ng/mL] was lower than that in the control group before the medical treatment [(15.13 ± 3.16)ng/mL],while the IL-4 level of patients in the treatment group [(1.64 ± 0.47) ng/mL] was higher than that in the control group [(0.72 ± 0.21) ng/mL] (t =2..93,3.52,all P ＜ 0.01).After 8 weeks' medical treatment,the IFN-γ level in culture supernatant of patients [(12.36 ± 2.56) ng/mL] increased obviously than that of before [(8.74 ± 1.37) ng/mL],while the IL-4 level [(1.21 ± 0.28) ng/mL] declined obviously than that of before [(1.64 ± 0.47) ng/mL] (t =2.36,2.31,all P ＜ 0.05).The total clinical efficiency of patients in the treatment group was 92.5 ％ (37/40).No serious drug adverse reaction (DAR) appeared during the medical treatment.Conclusion The Th1/Th2 cytokine unbalances in peripheral blood (PB) of allergic rhinitis patients.Montelukast has reliable curative effect with high security,whose mechanism of action has close effect on lowering the IL-4 in peripheral blood (PB),increasing the IFN-γ level in peripheral blood (PB),correcting the balance disorders of Th1/Th2 cytokine,and the transformation of immunity reaction from Th2 to Th1.
